Aspartate Aminotransferase-to-Platelet Ratio Index (APRi) as Biomarker for Liver Damage in Biliary Atresia (BA): A Meta-analysis
Topic overview
This correspondence addresses diagnostic accuracy considerations for using the APRI score as a non-invasive biomarker to assess liver damage in pediatric patients with biliary atresia. The authors respond to critiques of their meta-analysis examining APRI's clinical utility in this rare cholestatic liver disease.
Key takeaways
- APRi shows promise as a non-invasive biomarker for assessing liver damage severity in biliary atresia patients.
- Meta-analysis synthesizes evidence on APRi's diagnostic performance, informing clinical decision-making in BA management.
- Authors engage with peer critique on diagnostic accuracy metrics, refining interpretation of APRi utility in pediatric hepatology.
Keywords
Hashtags
Full article text
Full article text not available for this entry
How to cite: GlobalCastMD. Aspartate Aminotransferase-to-Platelet Ratio Index (APRi) as Biomarker for Liver Damage in Biliary Atresia (BA): A Meta-analysis. GlobalCastMD Medical Library. 2025-06-06. https://dev.library.globalcastmd.com/article/10566?via_space=staycurrentmd
Comments